Howard Leibowitz, MD
Internal Medicine · Worthington, MNNPI 1851363121
Payments from drug & device makers
Across 5 payments — averaging $489.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardinal Health 110 LLC$2K
- AstraZeneca$21
- Johnson & Johnson$14
- Sobi, Inc$13
What the payments were for
- Consulting fees$2,40098%
- Food & beverage$482%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardinal Health 110 LLC | 2 | $2,400 |
| AstraZeneca | 1 | $21 |
| Johnson & Johnson | 1 | $14 |
| Sobi, Inc | 1 | $13 |
How this compares
$2,448 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 112 | $44,890 |
| JanuviaSitagliptin Phosphate | 30 | $20,327 |
| OzempicSemaglutide | 11 | $11,294 |
| LinzessLinaclotide | 17 | $11,010 |
| JardianceEmpagliflozin | 34 | $10,343 |
| Spiriva HandihalerTiotropium Bromide | 12 | $9,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,727 |
| MyrbetriqMirabegron | 16 | $6,500 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $5,481 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 49 | $4,843 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,766 |
| FarxigaDapagliflozin Propanediol | 16 | $4,370 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,694 |
| Atorvastatin Calcium | 196 | $2,674 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $2,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $21 | $4,37016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,924 internal medicine providers in Minnesota.
Other internal medicine in Worthington
- Eusebio Emmanuel FerrerApple Valley$10.7M
- Dylan ZyllaSaint Louis Park$4M
- Shannon DoyleMaplewood$3.2M
- Robert PignoloRochester$2M
- Thomas MartensBrooklyn Center$1.3M
- Gregory PolandRochester$494K
- Patricia WalkerSaint Paul$356K
- Beth ThielenMinneapolis$343K
- Bruce JohnsonSt. Paul$284K
- James JohnsonMinneapolis$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.